Systolic heart failure
Therapeutic area
Cardiology
Rare disease
No
- Definition
- Heart failure caused by abnormal myocardial contraction during systole leading to defective cardiac emptying.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Systolic heart failure
- Therapeutic area
- Cardiology
- systolic heart failure
- Systolic Heart Failure (NYHA II-III)
- All therapeutic areas
- Cardiology
Sources for recorded values
- Severity
- Severe
- MONDO ID
- MONDO:0006993
- Parent condition
- MONDO:0005009
Related records
Broader conditions (7)
- Cardiovascular disorder
- Congestive heart failure
- Disease
- Disease by body system or component
- Heart disorder
- Heart failure
- Human disease
Trials (446)
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
- [11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection Fraction
- A Multicenter Trial of a Shared DECision Support Intervention for Patients Offered Implantable Cardioverter-DEfibrillators
- A Novel Home-based Physical Activity Intervention for Stable Chronic Heart Failure Patients
- A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)
- A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure
- A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea
- A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
- A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
- A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure
- A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction
- A Single-centre Research Study to Evaluate the Care4Today® Heart Failure Platform.
- A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure.
- A Study Investigating the Impact of IMT With CR On Exercise Responses In HF
- A Study of a Technology-enabled Disease Management Program to Reduce Hospitalizations for Heart Failure
- A Study of LY3971297 in Participants With Heart Failure
- A Study Of The Usage Of Statins In A Community Heart Failure Population
- A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)
- A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
- A Trial Comparing High-Flow Nasal Cannula Versus Noninvasive Ventilation on Reintubation and Post-Extubation Respiratory Failure in High-Risk Patients With Systolic Heart Failure
Approved drugs (2)
- Dapagliflozin
- Dapagliflozin propanediol
Drugs in development (17)
- Albumin human Phase 1
- Aliskiren Phase 2
- Anakinra Phase 2
- Dapansutrile Phase 1
- Human neuregulin-1 recombinant (177-237) Phase 3
- Ivabradine Phase 2
- Lenrispodun Phase 1
- Metformin Phase 2
- Nelutroctiv Phase 1
- Nesiritide Phase 1
- Niacin Phase 2
- Nicotinamide riboside Phase 1
- Nitric acid Phase 2
- Probenecid Phase 2
- Ramipril Phase 2
- Rifaximin Phase 2
- Udenafil Phase 3